Welcome to the News Room

Why not go the whole 9 yards?

Posted by:

If the proposed Preserve Access to Affordable Generics Act will generate savings for the US of $4.8 billion over 10 years (which is much less impressive when calculated on an annual basis, and that is without calculating the costs to the US economy by the negative implications of this legislation), why not go the whole 9 yards and axe the 180 days of market exclusivity to the first generic drug? After all, such a step could generate far greater savings due to immediate generic competition, right?

See the Congressional Budget Office’s report: http://aging.senate.gov/publications/s27.pdf


About the Author:

Rachel specialises in biomedical and energy-related innovation as well as international innovation policy. She has particular experience in sector-specific trend mapping, survey building and benchmarking of intellectual property environments. Rachel’s work focuses on Europe, with special emphasis on the UK and Spain, and she speaks fluent Spanish. She gained direct experience with UK innovation policy while interning with the UK’s then Department for Innovation, Universities and Skills.
  Related Posts
  • No related posts found.